Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of “Moderate Buy” by Brokerages
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price objective […]
More Stories
Columbia Sportswear (NASDAQ:COLM) Issues Q3 Earnings Guidance
Columbia Sportswear (NASDAQ:COLM – Get Free Report) issued an update on its third quarter earnings guidance on Thursday morning. The...
Boston Beer (NYSE:SAM) Announces Quarterly Earnings Results
Boston Beer (NYSE:SAM – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $4.39 earnings per...
Bitcoin Gold Market Cap Tops $457.42 Million (BTG)
Bitcoin Gold (BTG) traded up 4.7% against the dollar during the 1-day period ending at 22:00 PM Eastern on July...
AbbVie (NYSE:ABBV) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS
AbbVie (NYSE:ABBV – Get Free Report) posted its earnings results on Thursday. The company reported $2.65 EPS for the quarter,...
Bluzelle (BLZ) Trading 8.7% Lower Over Last Week
Bluzelle (BLZ) traded up 1% against the U.S. dollar during the one day period ending at 22:00 PM E.T. on...
Bitcoin Diamond (BCD) Tops 24-Hour Volume of $4,433.51
Bitcoin Diamond (BCD) traded 10.4% higher against the dollar during the twenty-four hour period ending at 22:00 PM Eastern on...